The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

Conclusions/interpretation: Single doses of empagliflozin 25 mg and 200 mg were not associated with QTcN prolongation and were well tolerated in healthy volunteers.Trial registration: ClinicalTrials.gov: NCT01195675

Source: Cardiovascular Diabetology - April 24, 2013 Category: Cardiology Authors: Arne RingTobias BrandSreeraj MachaKerstin Breithaupt-GroeglerGudrun SimonsBeate WalterHans WoerleUli Broedl Source Type: research